Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Operating Cash Flow per Share : NT$-1.42 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Operating Cash Flow per Share?

Great Novel Therapeutics Biotech & Medicals's operating cash flow per share for the six months ended in Dec. 2023 was NT$-0.70. Great Novel Therapeutics Biotech & Medicals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.42.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share or its related term are showing as below:

ROCO:7427' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -27.2 Med: 14.3 Max: 18.8
Current: 14.3

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 18.80% per year. The lowest was -27.20% per year. And the median was 14.30% per year.

ROCO:7427's 3-Year OCF Growth Rate is ranked better than
60.67% of 1233 companies
in the Biotechnology industry
Industry Median: 3.3 vs ROCO:7427: 14.30

Great Novel Therapeutics Biotech & Medicals Operating Cash Flow per Share Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Operating Cash Flow per Share Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.16

-2.24

-1.37

-2.38

-1.41

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial					-0.64	-0.88	-1.42	-0.72	-0.70

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Price-to-Operating-Cash-Flow falls into.

Great Novel Therapeutics Biotech & Medicals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-53.345	/	37.721
	=	-1.41

Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-27.701	/	39.865
	=	-0.69

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.42

Great Novel Therapeutics Biotech & Medicals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines